Keeps: Who It's Best For and Ideal Patient Profile

What Keeps Actually Prescribes

Keeps dispenses two FDA-approved medications for male androgenetic alopecia: oral finasteride 1 mg daily and topical minoxidil 5% solution or foam. Both drugs have decades of trial data behind them. Finasteride is a 5-alpha reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), the androgen responsible for miniaturizing hair follicles in genetically susceptible men.

The key registration trials for finasteride 1 mg enrolled 1,553 men aged 18 to 41 with mild-to-moderate vertex hair loss. At 2 years, 83% of finasteride-treated men maintained or increased hair count versus 28% on placebo, with a mean increase of 277 hairs in a 5.1 cm² target area (Kaufman et al., J Am Acad Dermatol, 1998). Five-year extension data confirmed durability: 48% of men on finasteride showed increased hair growth from baseline compared to a continued decline in the placebo group (Rossi et al., J Am Acad Dermatol, 2011).

Minoxidil 5% solution, the other pillar of the Keeps formulary, was evaluated in a 48-week randomized trial (N=393) showing a mean non-vellus hair count increase of 18.6 hairs/cm² with 5% solution versus 12.7 hairs/cm² with 2% solution (Olsen et al., J Am Acad Dermatol, 2002). The drug acts as a potassium channel opener and vasodilator, prolonging the anagen phase independent of the DHT pathway. That mechanistic difference is why clinicians frequently combine both drugs. A 2015 meta-analysis in Dermatologic Therapy found that combination finasteride-plus-minoxidil therapy produced superior hair density outcomes compared to either agent alone (Hu et al., 2015).

Keeps also offers a ketoconazole shampoo, though this is adjunctive rather than primary therapy.

The Ideal Keeps Patient: Early-to-Moderate Loss in Younger Men

The men who get the most out of Keeps share a few characteristics. They are typically between 18 and 50, have noticed thinning at the crown or a receding frontal hairline within the past one to five years, and fall between Norwood class II and IV on the Hamilton-Norwood scale.

This profile matters because pharmacologic response to finasteride and minoxidil is strongly time-dependent. A Japanese post-marketing study of 3,177 men taking finasteride 1 mg found that younger patients (under 40) and those treated earlier in their hair loss trajectory had significantly better outcomes at 12 months (Sato & Takeda, J Dermatol, 2012). Once follicles have fully miniaturized and the scalp appears smooth and shiny, no currently approved medication reliably reverses that loss. The biological window is real.

Men who fit the Keeps model also tend to be comfortable with a digital-first consultation. The platform uses asynchronous photo uploads reviewed by a licensed clinician. There is no video visit, no in-person exam, and no dermoscopy. For straightforward androgenetic alopecia, guidelines from the American Academy of Dermatology (AAD) support clinical diagnosis based on pattern recognition and history (Olsen et al., J Am Acad Dermatol, 2005). A photo-based approach can be adequate for this subset, though it cannot detect scarring alopecias, diffuse alopecia areata, or secondary causes like thyroid dysfunction.

Who should look elsewhere? Men over 50 with Norwood V or higher, men with patchy or diffuse loss that does not follow a classic androgenetic pattern, and anyone with scalp tenderness, scarring, or rapid onset. These presentations demand a biopsy or bloodwork that a photo-review platform cannot provide.

Is Keeps Legit? Evaluating the Clinical Model

The short answer: Keeps prescribes real, FDA-approved drugs through licensed providers. That part is straightforward. The more useful question is whether the telehealth delivery model compromises care quality.

A 2020 study in JAMA Dermatology examined direct-to-consumer platforms prescribing finasteride and found that most platforms did obtain relevant medical history, but few performed detailed differential diagnosis or discussed alternative diagnoses (Lee et al., JAMA Dermatol, 2020). The researchers submitted standardized patient cases, including one with features suggestive of alopecia areata rather than androgenetic alopecia. Several platforms still prescribed finasteride. This study did not single out Keeps specifically, but it highlighted a systemic weakness in asynchronous teledermatology for hair loss: pattern recognition from two-dimensional photos has limits.

For men with textbook Norwood II-IV pattern loss, no family history of autoimmune conditions, and no scalp symptoms beyond gradual thinning, the risk of misdiagnosis is low. The AAD's 2018 clinical practice guideline for androgenetic alopecia notes that the diagnosis "can usually be made on clinical grounds" when the pattern is classic (Adil & Godwin, Dermatol Ther, 2017). The Endocrine Society's 2017 guideline on testosterone therapy also acknowledges that male pattern hair loss in the presence of normal androgen levels is a clinical diagnosis (Bhasin et al., J Clin Endocrinol Metab, 2018).

Where Keeps falls short is follow-up granularity. In-person dermatologists can use trichoscopy to quantify miniaturization ratios, track vellus-to-terminal hair shifts, and identify early scarring features. Keeps relies on patient-submitted photos at follow-up intervals. That's adequate for many, but not for everyone.

Keeps vs. Alternatives: How the Platform Compares

Several direct-to-consumer platforms compete in the men's hair loss space, including Hims, Ro, and Happy Head. The drugs are the same across all of them. Finasteride 1 mg is finasteride 1 mg regardless of which platform ships it. The differentiators are pricing, formulation options, consultation depth, and add-on services.

Keeps historically positioned itself as a lower-cost option, with generic finasteride subscriptions starting around $10 per month. Hims offers similar pricing but has expanded into compounded topical finasteride-minoxidil combinations. Happy Head focuses on compounded multi-ingredient topicals. Ro (formerly Roman) bundles hair loss with a broader men's health platform.

A clinically relevant distinction: compounded topical finasteride (0.1% to 0.25%) combined with minoxidil in a single solution has shown promise in reducing systemic DHT suppression while maintaining scalp efficacy. A randomized controlled trial by Caserini et al. (2014) demonstrated that topical finasteride 0.25% achieved comparable scalp DHT reduction to oral finasteride 1 mg while producing 60 to 70% less systemic DHT suppression (Caserini et al., J Clin Pharmacol, 2014). For men concerned about sexual side effects, this matters. Keeps does not currently offer a compounded topical finasteride product, which limits its appeal for this subgroup.

The consultation model also varies. Hims and Ro offer synchronous video visits for some conditions. Keeps relies on the asynchronous photo review. Neither model is inherently superior for straightforward androgenetic alopecia, but the synchronous option provides an opportunity to ask questions in real time, which some men prefer during initial evaluation.

For men who want the simplest, most affordable path to generic finasteride and minoxidil with minimal friction, Keeps works well. For men who want compounded formulations, video-based consultations, or treatment of co-occurring conditions (erectile dysfunction, testosterone optimization), broader platforms may be more suitable.

What the Clinical Evidence Says About Long-Term Finasteride Use

Men starting finasteride through Keeps or any platform should understand the long-term data. The drug works, but it works only while you take it. Discontinuation leads to loss of gained hair within 6 to 12 months as DHT levels normalize.

The most commonly cited concern is sexual side effects. In the original key trials, 3.8% of finasteride-treated men reported decreased libido versus 2.1% on placebo, and 1.3% reported erectile dysfunction versus 0.7% on placebo (FDA label, finasteride 1 mg). These rates are low, and most resolved after discontinuation.

The concept of "post-finasteride syndrome" (persistent sexual, neurological, or psychological symptoms after stopping finasteride) has generated significant online discussion. A 2023 systematic review in the Journal of the European Academy of Dermatology and Venereology examined 38 studies and concluded that while a small subset of men report persistent symptoms, the evidence base is limited by lack of controlled prospective studies, potential nocebo effects, and selection bias in case series (Fertig et al., JEADV, 2023). The AAD does not recognize post-finasteride syndrome as an established diagnosis but recommends discussing potential sexual side effects before starting therapy.

A large-scale pharmacovigilance study using the FDA Adverse Event Reporting System found that the reporting rate for persistent sexual dysfunction with finasteride 1 mg was low relative to total prescriptions dispensed, though the authors noted underreporting as a limitation (Nguyen et al., Drug Saf, 2021). Men with pre-existing depression or anxiety may warrant closer monitoring, as some observational data suggest a modest association between finasteride use and depressive symptoms.

The bottom line for Keeps patients: discuss your psychiatric and sexual health history honestly during the intake questionnaire. If the platform's asynchronous model does not give you enough space to do that, consider a synchronous consultation elsewhere.

Setting Realistic Expectations for Keeps Users

Finasteride and minoxidil do not regrow a full head of hair. They slow loss and produce modest regrowth in a majority of users. Setting calibrated expectations reduces dropout, which is the biggest threat to treatment efficacy.

"The most important factor in successful treatment of androgenetic alopecia is realistic patient expectations," noted a 2019 expert consensus statement published in Dermatologic Surgery (Gupta et al., Dermatol Surg, 2019). Patients who expect dramatic transformation within weeks frequently abandon therapy before the 4-to-12-month timeline required for visible change.

Here is what the data supports: at 12 months of finasteride 1 mg, roughly 65% of men show some improvement in hair count, 83% maintain existing hair, and about 17% continue to lose despite treatment (Kaufman et al., 1998). Minoxidil 5% adds an independent growth stimulus, and combination therapy improves odds. But a Norwood IV patient will not return to Norwood I. The realistic outcome is stabilization with moderate cosmetic improvement at the vertex and midscalp. Frontal hairline regrowth is less reliable with either drug.

Keeps sends quarterly photo prompts to track progress. This is a good feature. Men should photograph their scalp under consistent lighting at baseline and every three months. If no change is visible at 12 months on combination therapy, the treatment is likely failing for that individual, and a referral to in-person dermatology for second-line options (platelet-rich plasma, low-level laser therapy, or surgical transplant evaluation) is appropriate.

When to Graduate Beyond Keeps

A subscription platform has limits. Keeps is a starting line, not a ceiling. Men who fail first-line medical therapy or who progress beyond Norwood IV territory need escalation.

Hair transplantation, either follicular unit extraction (FUE) or follicular unit transplantation (FUT), remains the definitive treatment for advanced androgenetic alopecia. The International Society of Hair Restoration Surgery (ISHRS) recommends that candidates be on stable medical therapy for at least 12 months before surgery to establish the pattern of loss and protect non-transplanted native hair (ISHRS Practice Census, 2022). Keeps-prescribed finasteride and minoxidil serve as excellent pre-surgical stabilization, even if the patient eventually needs a procedure.

Platelet-rich plasma (PRP) injections have emerging evidence, with a 2019 meta-analysis of 11 RCTs showing a weighted mean difference of +33.6 hairs/cm² versus baseline (Giordano et al., J Cosmet Dermatol, 2019). PRP requires in-office visits and is not available through Keeps or any direct-to-consumer platform.

Low-level laser therapy (LLLT) devices cleared by the FDA (e.g., HairMax LaserComb, iRestore) offer another adjunct. A 26-week sham-controlled trial found a 25.7% increase in terminal hair density with LLLT (Lanzafame et al., Lasers Surg Med, 2013). These devices can be used alongside Keeps prescriptions without platform involvement.

The decision tree is simple. Start with finasteride and minoxidil. Give it 12 months. Reassess with photos. If the trajectory is acceptable, continue. If not, consult a board-certified dermatologist or hair restoration surgeon for second-line therapy. Keeps can be the first step; it should not be the only one when the clinical picture demands more.